144 related articles for article (PubMed ID: 3904379)
1. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial.
Abrams J; Allen J; Allin D; Anderson J; Anderson S; Blanski L; Chadda K; DiBianco R; Favrot L; Gonzalez J
Am Heart J; 1985 Nov; 110(5):913-22. PubMed ID: 3904379
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerance of esmolol to propranolol for control of supraventricular tachyarrhythmia.
Morganroth J; Horowitz LN; Anderson J; Turlapaty P
Am J Cardiol; 1985 Oct; 56(11):33F-39F. PubMed ID: 2864847
[TBL] [Abstract][Full Text] [Related]
5. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
[TBL] [Abstract][Full Text] [Related]
6. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. The Esmolol Research Group.
Am Heart J; 1986 Sep; 112(3):498-505. PubMed ID: 2875641
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.
Das G; Tschida V; Gray R; Dhurandhar R; Lester R; McGrew F; Askenazi J; Kaplan K; Emanuele M; Turlapaty P
J Clin Pharmacol; 1988 Aug; 28(8):746-50. PubMed ID: 2905710
[TBL] [Abstract][Full Text] [Related]
8. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM; Schultz NJ; Tschida VH
Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.
Byrd RC; Sung RJ; Marks J; Parmley WW
J Am Coll Cardiol; 1984 Feb; 3(2 Pt 1):394-9. PubMed ID: 6141193
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of esmolol for unstable angina pectoris.
Wallis DE; Pope C; Littman WJ; Scanlon PJ
Am J Cardiol; 1988 Nov; 62(16):1033-7. PubMed ID: 2903659
[TBL] [Abstract][Full Text] [Related]
11. Effects of esmolol on airway function in patients with asthma.
Sheppard D; DiStefano S; Byrd RC; Eschenbacher WL; Bell V; Steck J; Laddu A
J Clin Pharmacol; 1986 Mar; 26(3):169-74. PubMed ID: 2870080
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and antiarrhythmic effects of esmolol in children.
Trippel DL; Wiest DB; Gillette PC
J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
[TBL] [Abstract][Full Text] [Related]
13. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
Reilly CS; Wood M; Koshakji RP; Wood AJ
Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
[TBL] [Abstract][Full Text] [Related]
14. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias.
Balser JR; Martinez EA; Winters BD; Perdue PW; Clarke AW; Huang W; Tomaselli GF; Dorman T; Campbell K; Lipsett P; Breslow MJ; Rosenfeld BA
Anesthesiology; 1998 Nov; 89(5):1052-9. PubMed ID: 9821992
[TBL] [Abstract][Full Text] [Related]
15. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
16. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D
Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
[TBL] [Abstract][Full Text] [Related]
17. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
[TBL] [Abstract][Full Text] [Related]
18. [A comparison of propranolol with esmolol for the treatment of tachycardia during emergence from anesthesia].
Mizutani K; Nakamura C; Tsuchiya M; Asada A
Masui; 2005 Jun; 54(6):632-7. PubMed ID: 15966380
[TBL] [Abstract][Full Text] [Related]
19. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Ko WJ; Chu SH
J Am Coll Cardiol; 1994 Feb; 23(2):302-6. PubMed ID: 7905013
[TBL] [Abstract][Full Text] [Related]
20. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias.
Schwartz M; Michelson EL; Sawin HS; MacVaugh H
Chest; 1988 Apr; 93(4):705-11. PubMed ID: 2894920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]